Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
BERKELEY, Calif., Feb. 28, 2017 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that it will present at two investor conferences in March 2017. On Monday, March 6, 2017 at 4:40 pm Eastern Time, Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 37th Cowen and Company Annual Healthcare Conference in Boston, MA. On Monday, March 13, 2017 at 10:00 am Pacific Time, Gregory W. Schafer, chief operating officer of Aduro, will present at the 29th Annual ROTH Conference in Dana Point, CA.
To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 [email protected]
